Uveal Melanoma

Tebentafusp for patients with HLA-A*02:01-positive mUM is associated with improved survival outcomes and manageable toxicity. These findings support tebentafusp as the standard of care for this patient population.

This cross-racial UM study reveals significant molecular and immune differences, indicating that Asian UM may be more responsive to immunotherapy The population-specific prognostic model improves our understanding of molecular differences in Asian and Caucasian UM, warranting further validation in multiethnic cohorts.

Considering the prognostic implications of DLAT in tumors and its correlations with immune indicators, it is plausible to regard DLAT as both a prognosis feature for certain malignancies and an evaluative metric for immunotherapy efficacy. The findings suggest that DLAT could be a potential therapeutic target and serve as a biomarker for predicting patient outcomes and guiding treatment strategies in various cancers, with its prognostic and immunological implications likely to be context-dependent across different tumor types.

P=N/A, N=50, Active, not recruiting, Centre Jean Perrin | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2026

Co-occurrence of GNAQ, GNAS, and IDH1 mutations may represent a molecular signature of recurrence. Further validation in larger cohorts is needed to define optimal gene panels and VAF thresholds for clinical use.

P1/2, N=36, Recruiting, Novelwise Pharmaceutical Corporation | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> Aug 2029

P1/2, N=109, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Aug 2032 | Trial primary completion date: May 2030 --> Oct 2030

This pan-cancer and single-cell integrative analysis highlights the complex roles of RBPs in cancer progression and their potential as prognostic biomarkers, particularly RBP4 and RBP7 in breast cancer. These findings warrant further investigation into the functional mechanisms of RBPs, which may provide valuable strategies for therapeutic interventions.

Furthermore, transcriptomic profiling revealed broad gene expression changes upon BAP1 restoration, suggesting that these combined alterations contribute to the re-establishment of anchorage-dependent growth in KMRC-20 cells. These findings uncover a previously unrecognized role for BAP1 in suppressing anchorage-independent survival, providing new insights into BAP1-driven tumorigenesis and underscoring the therapeutic potential of precise gene editing to restore tumor suppressor function in ccRCC.

Mild retinal disorganization across multiple imaging modalities expands the ocular phenotype of BHD and likely arises from defects in cellular adhesion mediated by FLCN. Larger cohorts of patients with BHD may be necessary to establish these ocular imaging abnormalities as part of the BHD phenotypic spectrum.

P2, N=51, Active, not recruiting, Institut Curie | Trial primary completion date: May 2025 --> Oct 2026